Bristol-Myers Squibb Co
BMY54.670USD
-0.040-0.07%
終値 12/26, 16:00（ET）15分遅れの株価
111.31B時価総額
18.40直近12ヶ月PER
詳細情報 Bristol-Myers Squibb Co 企業名
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Coの企業情報
企業コードBMY
会社名Bristol-Myers Squibb Co
上場日Mar 17, 1980
最高経営責任者「CEO」Boerner (Christopher S)
従業員数34100
証券種類Ordinary Share
決算期末Mar 17
本社所在地Route 206 And Province Line Road
都市PRINCETON
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号08543
電話番号16092524621
ウェブサイトhttps://www.bms.com
企業コードBMY
上場日Mar 17, 1980
最高経営責任者「CEO」Boerner (Christopher S)
Bristol-Myers Squibb Coの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
他の
3.47B
28.29%
地域別USD
会社名
収益
比率
United States
8.52B
69.44%
International
3.48B
28.37%
other
270.00M
2.20%
事業別
地域別
事業別USD
会社名
収益
比率
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
他の
3.47B
28.29%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
他の
74.21%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
他の
74.21%
種類
株主統計
比率
Investment Advisor
44.02%
Investment Advisor/Hedge Fund
25.70%
Research Firm
2.97%
Pension Fund
2.51%
Hedge Fund
2.51%
Bank and Trust
2.22%
Sovereign Wealth Fund
1.74%
Insurance Company
0.19%
Family Office
0.06%
他の
18.08%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
3973
1.68B
84.73%
-171.91K
2025Q3
4147
1.68B
85.10%
-5.79M
2025Q2
4212
1.69B
83.90%
+15.56M
2025Q1
4284
1.67B
82.20%
-238.41K
2024Q4
4280
1.64B
80.20%
+45.34M
2024Q3
4106
1.59B
79.76%
+6.69M
2024Q2
4097
1.58B
82.24%
-51.64M
2024Q1
4107
1.64B
80.22%
+12.13M
2023Q4
4104
1.60B
80.80%
-21.68M
2023Q3
4025
1.62B
80.17%
-24.04M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
193.94M
9.53%
+3.47M
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
99.37M
4.88%
+1.60M
+1.64%
Jun 30, 2025
State Street Investment Management (US)
94.74M
4.65%
-94.48K
-0.10%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
70.80M
3.48%
+10.20M
+16.82%
Jun 30, 2025
JP Morgan Asset Management
67.41M
3.31%
-2.47M
-3.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
46.18M
2.27%
+723.46K
+1.59%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
33.57M
1.65%
-1.60M
-4.55%
Jun 30, 2025
Capital International Investors
66.16M
3.25%
-303.34K
-0.46%
Jun 30, 2025
Columbia Threadneedle Investments (US)
29.38M
1.44%
+350.53K
+1.21%
Jun 30, 2025
PRIMECAP Management Company
22.94M
1.13%
-25.98K
-0.11%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Fri, Dec 5
更新時刻: Fri, Dec 5
銘柄名
比率
VanEck Pharmaceutical ETF
9.15%
First Trust NASDAQ Pharmaceuticals ETF
7.58%
Franklin US Dividend Booster Index ETF
5.08%
WBI Power Factor High Dividend ETF
4.88%
VanEck Morningstar Wide Moat Value ETF
4.34%
iShares U.S. Pharmaceuticals ETF
4.31%
Schwab U.S. Dividend Equity ETF
3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
3.68%
ETC 6 Meridian Mega Cap Equity ETF
3.58%
Brookstone Value Stock ETF
3.48%
詳細を見る
VanEck Pharmaceutical ETF
比率9.15%
First Trust NASDAQ Pharmaceuticals ETF
比率7.58%
Franklin US Dividend Booster Index ETF
比率5.08%
WBI Power Factor High Dividend ETF
比率4.88%
VanEck Morningstar Wide Moat Value ETF
比率4.34%
iShares U.S. Pharmaceuticals ETF
比率4.31%
Schwab U.S. Dividend Equity ETF
比率3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
比率3.68%
ETC 6 Meridian Mega Cap Equity ETF
比率3.58%
Brookstone Value Stock ETF
比率3.48%
配当金
過去5年間の配当金総支払額は
22.71B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Dec 10, 2025
BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option
Jan 02, 2026
Feb 02, 2026
Jan 02, 2026
Sep 17, 2025
BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option
Oct 03, 2025
Nov 03, 2025
Oct 03, 2025
Jun 17, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option
Jul 03, 2025
Aug 01, 2025
Jul 03, 2025
Mar 03, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option
Apr 04, 2025
May 01, 2025
Apr 04, 2025
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
詳細を見る
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Bristol-Myers Squibb Coの上位5名の株主は誰ですか？
Bristol-Myers Squibb Coの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は193.94M株を保有しており、これは全体の9.53%に相当します。
BlackRock Institutional Trust Company, N.A.は99.37M株を保有しており、これは全体の4.88%に相当します。
State Street Investment Management (US)は94.74M株を保有しており、これは全体の4.65%に相当します。
Charles Schwab Investment Management, Inc.は70.80M株を保有しており、これは全体の3.48%に相当します。
JP Morgan Asset Managementは67.41M株を保有しており、これは全体の3.31%に相当します。
The Vanguard Group, Inc.は193.94M株を保有しており、これは全体の9.53%に相当します。
BlackRock Institutional Trust Company, N.A.は99.37M株を保有しており、これは全体の4.88%に相当します。
State Street Investment Management (US)は94.74M株を保有しており、これは全体の4.65%に相当します。
Charles Schwab Investment Management, Inc.は70.80M株を保有しており、これは全体の3.48%に相当します。
JP Morgan Asset Managementは67.41M株を保有しており、これは全体の3.31%に相当します。
Bristol-Myers Squibb Coの株主タイプ上位3種は何ですか？
Bristol-Myers Squibb Coの株主タイプ上位3種は、
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Bristol-Myers Squibb Co（BMY）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Bristol-Myers Squibb Coの株式を保有している機関は3973社あり、保有株式の総市場価値は約1.68Bで、全体の84.73%を占めています。2025Q3と比較して、機関の持ち株は-0.37%増加しています。
Bristol-Myers Squibb Coの最大の収益源は何ですか？
FY2025Q2において、Eliquis部門がBristol-Myers Squibb Coにとって最大の収益を生み出しており、その金額は3.68Bで、全収益の30.00%を占めています。
